G-BA assesses Sanofi's Zaltrap

Germany's Federal Joint Committee (G-BA) said Zaltrap aflibercept from Sanofi (Euronext:SAN; NYSE:SNY) has "marginal" additional benefit to treat metastatic colorectal cancer (mCRC) vs. FOLFIRI chemotherapy. G-BA's final benefit assessment is in line with a preliminary assessment from Germany's Institute for Quality and Efficiency in Healthcare (IQWiG). Sanofi will now negotiate a price for Zaltrap with Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband) (see BioCentury Extra, June 3). ...